HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on Pyxis Oncology (NASDAQ:PYXS) and raises the price target from $4 to $7.
March 22, 2024 | 10:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Pyxis Oncology and raises the price target from $4 to $7.
The upgrade in price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong confidence in the company's future performance. This can lead to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100